Methscopolamine (methscopolamine bromide)

Methscopolamine bromide is a semisynthetic quaternary ammonium antimuscarinic.

Methscopolamine bromide is used as an adjunct in the treatment of peptic ulcer disease. As with other antimuscarinics, there are no conclusive data from well-controlled studies that indicate that, in the usually recommended dosage, methscopolamine aids in the healing, decreases the rate of recurrence, or prevents complications of peptic ulcers. In addition, in patients with gastric ulcer, antimuscarinics may delay gastric emptying and result in antral stasis.

With the advent of more effective therapies for the treatment of peptic ulcer disease, antimuscarinics have only limited usefulness in this condition. Current epidemiologic and clinical evidence supports a strong association between gastric infection with Helicobacter pylori and the pathogenesis of duodenal and gastric ulcers, and the American College of Gastroenterology (ACG), the National Institutes of Health (NIH), and most clinicians currently recommend that all patients with initial or recurrent duodenal or gastric ulcer and documented H. pylori infection receive anti-infective therapy for treatment of the infection. For a more complete discussion of H. pylori infection, including details about the efficacy of various regimens and rationale for drug selection, see Uses: Helicobacter pylori Infection, in Clarithromycin 8:12.12.92.

Generic name: methscopolamine bromide
Pronunciation: (METH-skoe-POL-a-meen)

The following indications are listed for Methscopolamine:

• Peptic Ulcer

Also known as: Gastroduodenal Ulcer, Peptic Ulcer Disease, Ulcer Of The Stomach Or Duodenum.

No ICD codes are available for this drug.